CINACALCET FOR MANAGING SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS IN CLINICAL PRACTICE IN BELGIUM: A 16-MONTH OBSERVATIONAL STUDY (ECHO-B)

Debellé, Frederic; Meeus, Gert; Dratwa, Max; Maes, Bart; Vanholder, Raymond; P. Albert, Anthony; Schutyser, Evemie; Jadoul, Michel

doi:10.2143/acb.3231

Public

CINACALCET FOR MANAGING SECONDARY HYPERPARATHYROIDISM IN DIALYSIS PATIENTS IN CLINICAL PRACTICE IN BELGIUM: A 16-MONTH OBSERVATIONAL STUDY (ECHO-B)

Published in Acta Clinica Belgica • Jul 1, 2013

Authors:

Frederic Debellé

Gert Meeus

Max Dratwa

Abstract

In Belgium, the calcimimetic cinacalcet is initially reimbursed for or = 800 pg/mL, or iPTH 300-800 pg/ mL and Ca x P > 55 mg 2/dL2 despite > or = 6 months' optimal treatment with vitamin D sterols and/or phosphate binders. The Belgian, multicentre, observational study ECHO-B evaluated cinacalcet in...

Subject

Cinacalcet

Medicine

Calcimimetic

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!